BBOT vs TPVG vs BBIO vs HRZN vs KYMR

For growth investors, BridgeBio Pharma, Inc.

(BBIO) is the stronger pick with 126. 3% revenue growth year-over-year, versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). Horizon Technology Finance Corporation (HRZN) offers the better valuation at 4. 3x trailing P/E (6. 0x forward), making it the more compelling value choice. Analysts rate BridgeBio Oncology Therapeutics Inc. (BBOT) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Horizon Technology Finance Corporation (HRZN) is the cheapest at 4.

3x versus TriplePoint Venture Growth BDC Corp. at 4. 7x. On forward P/E, Horizon Technology Finance Corporation is actually cheaper at 6. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Horizon Technology Finance Corporation wins at 0. 25x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +95. 8%, compared to -31. 4% for Horizon Technology Finance Corporation (HRZN). Over 10 years, the gap is even starker: KYMR returned +158. 8% versus BBOT's -24. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Horizon Technology Finance Corporation (HRZN) is the lower-risk stock at 0.

77β versus BridgeBio Pharma, Inc. 's 1. 21β — meaning BBIO is approximately 58% more volatile than HRZN relative to the S&P 500. On balance sheet safety, BridgeBio Oncology Therapeutics Inc. (BBOT) carries a lower debt/equity ratio of 1% versus 149% for Horizon Technology Finance Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BridgeBio Pharma, Inc.

(BBIO) is pulling ahead at 126. 3% versus -16. 7% for Kymera Therapeutics, Inc. (KYMR). On earnings-per-share growth, the picture is similar: Horizon Technology Finance Corporation grew EPS 756. 3% year-over-year, compared to -1034. 8% for BridgeBio Oncology Therapeutics Inc.. Over a 3-year CAGR, BBIO leads at 86. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TriplePoint Venture Growth BDC Corp.

(TPVG) is the more profitable company, earning 50. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 50. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TPVG leads at 77. 9% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Horizon Technology Finance Corporation (HRZN) is the more undervalued stock at a PEG of 0. 25x versus TriplePoint Venture Growth BDC Corp. 's 6. 14x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Horizon Technology Finance Corporation (HRZN) trades at 6. 0x forward P/E versus 6. 2x for TriplePoint Venture Growth BDC Corp. — 0. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BBOT: 182. 9% to $21. 67.

In this comparison, HRZN (27.

6% yield), TPVG (17. 8% yield) pay a dividend. BBOT, BBIO, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TriplePoint Venture Growth BDC Corp.

(TPVG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 77), 17. 8% yield). Both have compounded well over 10 years (TPVG: +91. 2%, BBIO: +144. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BBOT (Healthcare) and TPVG (Financial Services) and BBIO (Healthcare) and HRZN (Financial Services) and KYMR (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BBOT is a small-cap quality compounder stock; TPVG is a small-cap high-growth stock; BBIO is a mid-cap high-growth stock; HRZN is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock. TPVG, HRZN pay a dividend while BBOT, BBIO, KYMR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.